A history of multiple sclerosis clinical trials and drug development, from Charcot’s 1868 description to modern DMT approvals and MRI biomarkers.
For centuries, MS was recognized as a condition characterized by episodic and progressive neurological deterioration, classified as “paraplegia”.
Today, multiple sclerosis is one of the most active areas of neurological drug development, with more than 20 disease-modifying therapies approved across different MS phenotypes and regulatory jurisdictions.
This timeline traces the clinical, regulatory, and imaging milestones that shaped modern MS clinical trials — from Charcot’s first formal description of the disease to the growing role of MRI biomarkers in diagnosis, patient stratification, and treatment monitoring.
Related reading: Central Vein Sign: A Breakthrough in Multiple Sclerosis Diagnosis and The New McDonald Criteria: Is Your MS Study Ready?.
Multiple sclerosis was first systematically described as a clinical entity by French neurologist Jean-Martin Charcot in 1868, who termed it “la sclérose en plaques disséminées”. Charcot identified the characteristic neurological triad of nystagmus, intention tremor, and scanning speech, and described plaques of demyelination in the brain and spinal cord on post-mortem examination.
This work established MS as a distinct neurological condition, separating it from broader descriptions of progressive neurological deterioration that had previously been grouped under terms such as “paraplegia”.
As neurology advanced, MS diagnosis shifted from descriptive clinical observation toward more standardised diagnostic frameworks. Clinicians increasingly recognised that MS could present in different forms, including relapsing and progressive patterns.
This distinction later became essential for clinical trial design, because disease phenotype determines eligibility criteria, endpoint selection, treatment expectations, and regulatory strategy.
The first disease-modifying therapy approved for multiple sclerosis was interferon beta-1b, marketed as Betaferon or Betaseron. It received FDA approval in 1993, marking the start of the modern disease-modifying therapy era in MS.
Its approval established a new regulatory model for MS drug development, where relapse reduction, disability progression, and MRI-based measures became central to evaluating therapeutic benefit.
The approval of interferon beta-1b marked the beginning of the modern disease-modifying therapy era in MS.
MRI changed the MS clinical trial landscape by providing objective and reproducible measures of disease activity. MRI endpoints such as T2 lesion burden, gadolinium-enhancing lesions, new or enlarging lesions, and brain atrophy became increasingly important in both clinical research and regulatory submissions.
Unlike clinical assessments alone, MRI can detect subclinical disease activity and longitudinal changes that may not yet be visible through symptoms or disability scales.
MRI has become one of the most important tools for detecting disease activity and monitoring treatment response in MS clinical trials.
Modern MS clinical trials are shaped by the recognised heterogeneity of the disease. The major clinical phenotypes include clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS, primary progressive MS, and active or non-active progressive disease.
Each phenotype requires different eligibility criteria, endpoint strategies, imaging protocols, and study durations. This is one reason why patient stratification has become a major priority in MS drug development.
As of 2024, more than 20 disease-modifying therapies have received regulatory approval for MS across different phenotypes and jurisdictions. These include interferon beta formulations, glatiramer acetate, S1P receptor modulators, anti-CD20 monoclonal antibodies, natalizumab, alemtuzumab, cladribine, and dimethyl fumarate.
The expansion of therapeutic options has increased the need for more precise trial design, better patient selection, and more sensitive biomarkers that can differentiate mechanisms of action and treatment effects.
Advanced MRI biomarkers are increasingly important in MS research and clinical trial design. Imaging markers such as the central vein sign and paramagnetic rim lesions are helping improve diagnostic specificity and identify biologically meaningful disease activity.
These developments are especially relevant for clinical trials, where reducing diagnostic uncertainty and improving patient stratification can directly affect trial power, study cost, and the likelihood of detecting a treatment effect.
The history of MS drug development shows a clear pattern: progress accelerates when clinical insight, imaging technology, and regulatory frameworks move together.
For sponsors and research teams, the next phase of MS clinical trials will likely depend on more precise imaging workflows, better biomarker integration, and scalable infrastructure for managing multi-site MRI data.
Multiple sclerosis was first systematically described as a clinical entity by French neurologist Jean-Martin Charcot in 1868, who termed it 'la sclérose en plaques disséminées'. Charcot identified the characteristic neurological triad of nystagmus, intention tremor, and scanning speech, and described the plaques of demyelination in the brain and spinal cord on post-mortem examination. His work established MS as a distinct condition separate from other causes of progressive neurological deterioration, which had previously been classified broadly as 'paraplegia'.
The first disease-modifying therapy (DMT) approved for multiple sclerosis was interferon beta-1b (Betaferon/Betaseron), which received FDA approval in 1993 — 125 years after Charcot's original description. Its approval was based on the pivotal clinical trial demonstrating a 34% reduction in relapse rate in relapsing-remitting MS patients. This marked the beginning of the modern DMT era in MS and established the template for subsequent regulatory submissions in MS, including the use of MRI lesion counts and relapse rates as primary endpoints.
MRI has been central to MS clinical trial design since the 1990s, providing objective, reproducible measures of disease activity and progression that are more sensitive than clinical assessments alone. MRI endpoints — including T2 lesion count and volume, Gd-enhancing lesions, and brain atrophy — now form an essential component of the McDonald diagnostic criteria and are primary or secondary endpoints in virtually all modern MS trials. More recently, advanced MRI biomarkers including the central vein sign (CVS) and paramagnetic rim lesions (PRLs) have been incorporated into the 2024 McDonald Criteria update, further improving diagnostic specificity.
Multiple sclerosis is recognised in five major clinical phenotypes that affect trial design: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS — the most common form, affecting ~85% of patients at diagnosis), secondary progressive MS (SPMS), primary progressive MS (PPMS), and active vs. non-active progressive forms. Each phenotype has distinct clinical trial eligibility criteria, endpoint requirements, and regulatory expectations. The heterogeneity of MS phenotypes is one reason why precise patient stratification — enabled by advanced imaging biomarkers — is increasingly important for trial success.
As of 2024, more than 20 disease-modifying therapies have received regulatory approval for multiple sclerosis across various phenotypes and regulatory jurisdictions. These span several therapeutic classes including interferon beta formulations, glatiramer acetate, S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod), anti-CD20 monoclonal antibodies (ocrelizumab, ofatumumab, ublituximab), natalizumab, alemtuzumab, cladribine, and dimethyl fumarate. Each approval has been supported by imaging endpoints alongside clinical outcomes, reflecting the central role of MRI in the MS drug development evidence base.
Author: Oscar Peña, QMENTA
Learn how QMENTA simplifies central vein detection in Multiple Sclerosis. Our solution automates protocol adherence, sequence recognition, and white...
Discover how the new McDonald criteria use imaging biomarkers such as the Central Vein Sign (CVS) to make earlier, more accurate MS diagnosis
QMENTA’s AI Platform Selected for the CAVS-MS Multiple Sclerosis Biomarker...